ArticleScientific reports2025
Unveiling CCR9 and CCL13 as immune biomarkers and therapeutic targets in thymoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study employed bioinformatics to identify immune-related diagnostic and therapeutic target genes in thymoma, offering a theoretical foundation for clinical diagnosis and treatment of the disease. In this study, machine learning techniques were employed to identify and validate potential biomarkers, leading to the construction of a diagnostic nomogram. Immune infiltration analysis was subsequently conducted to explore the relationships between these biomarkers and immune cell populations. Finally, the findings were validated through RT-qPCR and Western blotting experiments, ensuring the robustness of the results. Three critical biomarkers were selected for thymoma, with CCR9 and CCL13 confirmed as the final biomarkers through ROC analysis, both demonstrating AUC values exceeding 0.7. Immune infiltration analysis revealed significant differences in 14 types of immune cells between the thymoma and control groups, highlighting a strong association between macrophages and the biomarkers. A nomogram for thymoma was constructed using these 2 biomarkers, exhibiting robust performance. Ultimately, validation experiments using RT-qPCR and Western blotting confirmed the consistency of CCR9 and CCLI3 expression with the bioinformatics results. CCR9 and CCL13 were identified in this study as immune-related biomarkers associated with thymoma, which might provide a theoretical foundation for the development of targeted gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.